Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 3NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 9Gynecologic 8Breast 8Gastrointestinal 6Other solid neoplasm 2Dermatologic 2Tumor-Agnostic 1Genitourinary 1CNS 1

Conditions

Neoplasms 1

Interventions

pembrolizumab 62Paclitaxel 51Gemcitabine 50Carboplatin 45Docetaxel 43Cisplatin 31Pemetrexed 30Nivolumab 28Bevacizumab 28atezolizumab 22Fluorouracil 22Cetuximab 21Capecitabine 21Irinotecan 20Leucovorin 19Afatinib 18Erlotinib Hydrochloride 15trametinib 14Trastuzumab 13Ipilimumab 13130-nm albumin-bound paclitaxel 13regorafenib 11olaparib 11Sorafenib 11Oxaliplatin 11Drug Therapy 11eribulin 10enzalutamide 10Midazolam 10Injections 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × veliparib × Tumor-Agnostic × Clear all
NCT01853306 2017-11-21

A Study to Evaluate the Safety, Pharmacokinetics and Oral Bio Availability of Veliparib in Subjects With Solid Tumors

AbbVie

Phase 1 Completed
71 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡